Calendar ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
8.35 USD +3.21% Intraday chart for ARS Pharmaceuticals, Inc. -1.42% +52.37%

Chart calendar ARS Pharmaceuticals, Inc.

b801b.hAtk-33sDxLQd6y_J6bzUewXaaCEZpUyJXT_qr9qTWg.9mopyTKjYyaPKP_cbcyBJph4AvL2Ud9gFESI3-snIB3WRz29FtxqX6Ed6Q~38a80cb2b0dbc763f8cc12eb15001158

Upcoming events on ARS Pharmaceuticals, Inc.

2024-05-12 Q1 2024 Earnings Release (Projected)
2024-08-07 Q2 2024 Earnings Release (Projected)
2024-11-06 Q3 2024 Earnings Release (Projected)
2025-03-19 Q4 2024 Earnings Release (Projected)

Past events on ARS Pharmaceuticals, Inc.

2024-03-21 16:05 Q4 2023 Earnings Release
2024-03-13 10:00 Leerink Partners Global Biopharma Conference - Fireside Chat
2024-03-07 13:00 Investor Day
2024-02-26 12:45 American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: 788
2024-02-24 09:45 American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: 240
2024-02-24 09:45 American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: L32
2024-02-24 09:45 American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: 299
2024-02-23 15:15 American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: 033
2023-11-12 14:35 American College of Allergy Asthma and Immunolog Scientific Meeting
2023-11-11 19:30 American College of Allergy Asthma and Immunolog Scientific Meeting
2023-11-10 20:45 American College of Allergy Asthma and Immunolog Scientific Meeting
2023-11-10 19:30 American College of Allergy Asthma and Immunolog Scientific Meeting
2023-11-09 16:00 Q3 2023 Earnings Release
2023-08-10 16:00 Q2 2023 Earnings Release
2023-06-27 12:00 Annual General Meeting
2023-05-15 09:00 Q1 2023 Earnings Release
2023-03-23 16:01 Q4 2022 Earnings Release
2023-02-24 15:15 American Academy of Allergy, Asthma & Immunology Meeting - Results of a Patient/Caregiver Survey
2023-02-24 15:15 American Academy of Allergy, Asthma & Immunology Meeting - Epinephrine Auto-Injector-Prescriptions N
2023-02-24 15:15 American Academy of Allergy, Asthma & Immunology Meeting - 1.0 mg and 2.0 mg Doses

Annual results

Fiscal PeriodDecember 2021 2022 2023 2024
Net sales
Million USD
Released
Forecast
Spread
0,00


1,32
1,27
3.89%
0,03
0,01
200%

5,54

EBITDA
Released
Forecast
Spread
0,00


0,00
0,00
-
0,00
0,00
-

0,00

EBIT
Million USD
Released
Forecast
Spread
0,00


-35,5
-76,8
53.78%
-67,5
-76,2
11.36%

-64,9

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
0,00


-34,7
-74,8
53.65%
-54,4
-63,6
14.53%

-55,4

Net income
Million USD
Released
Forecast
Spread
-20,2


-34,7
-73,2
52.63%
-54,4
-60,8
10.58%

-59,2

EPS
USD
Released
Forecast
Spread
-0,83


-0,87
-1,33
34.34%
-0,57
-0,64
10.94%

-0,61

Announcement Date06/10/2223/03/2321/03/24-

Quarterly results

Fiscal PeriodDecember 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales
Million USD
Released
Forecast
Spread
0,00
0,10
-
0,02
0,00
-
0,01
0,00
-
0,00
0,00
-
0,00
0,00
-

0,00


0,00


1,00


4,34


2,80

EBIT
Million USD
Released
Forecast
Spread
-15,4
-12,1
-27.38%
-18,7
-18,0
-4.08%
-20,6
-20,3
-1.25%
-18,0
-21,0
14.34%
-57,3
-17,5
-228.25%

-10,2


-11,1


-18,8


-24,7




Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
-14,4
-12,9
-11.78%
-15,0
-17,6
14.88%
-17,4
-18,4
5.63%
-14,9
-18,8
20.71%
-7,17
-15,0
52.25%

-7,49


-8,48


-16,7


-22,7




Net income
Million USD
Released
Forecast
Spread
-14,4
-12,9
-11.78%
-15,0
-15,8
5.01%
-17,4
-16,4
-6.1%
-14,9
-17,5
15.21%
-7,17
-13,6
47.33%

-10,4


-12,5


-16,2


-20,1




EPS
USD
Released
Forecast
Spread
-0,09
-0,14
35.71%
-0,16
-0,17
4%
-0,18
-0,17
-3.85%
-0,16
-0,18
12.73%
-0,07
-0,14
50%

-0,11


-0,13


-0,17


-0,21


-0,19

Announcement Date23/03/2315/05/2310/08/2309/11/2321/03/24-----

Net sales - Quarter - Rate of surprise

Quarterly earnings - Rate of surprise

Net sales - Annual - Rate of surprise

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. SPRY Stock
  4. Calendar ARS Pharmaceuticals, Inc.